Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 7 years of Asset Writedowns and Impairment data on record, last reported at $14.8 million in Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $14.8 million; the TTM value through Dec 2025 reached $14.8 million, up 2383.22%, while the annual FY2025 figure was $14.8 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $14.8 million in Q2 2025 per LCTX's latest filing, up from $148000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $14.8 million in Q2 2025 and bottomed at $14.8 million in Q2 2025.